Kinetics of peg-filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplantation

ABSTRACT Peg-filgrastim is a form of G-CSF with a sustained duration of action due to self-limited clearance. We administered 6 mg peg-filgrastim to 18 autograft recipients on day +1 after

transplantation for hematologic malignancies. Plasma samples were collected at baseline and during transplantation. Hematopoietic recovery and clinical outcomes were compared to the

historical data of 54 patients not receiving G-CSF. Patients receiving peg-filgrastim achieved a serum level of 115 000 pg/ml on day +2, 24 h after drug administration. Drug level maintained

a plateau until day +8 and, after day +10, declined concomitantly with myeloid recovery. Patients experienced prompt neutrophil recovery: days +9 and +10 to 500 and 1000 neutrophils per

microliter, and 4 days with an absolute neutrophil count <100 cells per microliter. Duration of antibiotic therapy was significantly shortened, but we did not observe significant

differences in other end points. In conclusion, peg-filgrastim was well tolerated and efficacious, and hastened myeloid recovery. Access through your institution Buy or subscribe This is a

preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per

year only $21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated

during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS IMPACT OF

SINGLE DOSE OF PEGFILGRASTIM ON PERIPHERAL BLOOD STEM CELL HARVEST IN PATIENTS WITH MULTIPLE MYELOMA OR MALIGNANT LYMPHOMA Article Open access 25 April 2025 MOBILIZATION STRATEGIES WITH AND

WITHOUT PLERIXAFOR FOR AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA Article 31 July 2024 REDUCED DOSE OF POSTTRANSPLANT CYCLOPHOSPHAMIDE IN HLA-HAPLOIDENTICAL PERIPHERAL

BLOOD STEM CELL TRANSPLANTATION Article 24 September 2020 REFERENCES * Tarella C, Castellino C, Locatelli F, Caracciolo D, Corradini P, Falda M _et al_. G-CSF administration following

peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. _Bone Marrow Transplant_ 1998; 21: 401–407.

Article  CAS  PubMed  Google Scholar  * Kodo H, Tajika K, Takahashi S, Ozawa K, Asano S, Takaku F . Acceleration of neutrophilic granulocyte recovery after bone marrow transplantation by

administration of recombinant human granulocyte colony stimulating factor. _Lancet_ 1988; 2: 38–39. Article  CAS  PubMed  Google Scholar  * Sheridan WP, Morstyn G, Wolf M, Dodds A, Lusk J,

Maher D _et al_. Granulocyte-colony stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. _Lancet_ 1989; 2: 891–895. Article 

CAS  PubMed  Google Scholar  * Stahel RA, Jost LM, Cerny T, Pichert G, Honegger H, Tobler A _et al_. Randomized study of recombinant human granulocyte colony-stimulating factor after

high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. _J Clin Oncol_ 1994; 12: 1931–1938. Article  CAS  PubMed  Google Scholar  * Linch DC,

Milligan DW, Winfield DA, Kelsey SM, Johnson SA, Littlewood TJ _et al_. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil

recovery and shortened time in hospital: results of a randomized BNLI trial. _Br J Haematol_ 1997; 99: 933–938. Article  CAS  PubMed  Google Scholar  * Spitzer G, Adkins DR, Spencer V,

Dunphy FR, Petruska PJ, Velasquez WS _et al_. Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. _J

Clin Oncol_ 1994; 12: 661–670. Article  CAS  PubMed  Google Scholar  * Shimazaki C, Oku N, Uchiyama H, Yamagata N, Tatsumi T, Hirata T _et al_. Effect of granulocyte-colony stimulating

factor on hematopoietic recovery after peripheral blood progenitor cell transplantation. _Bone Marrow Transplant_ 1994; 13: 271–275. CAS  PubMed  Google Scholar  * Cortelazzo S, Viero P,

Bellavita P, Rossi A, Buelli M, Borleri GM _et al_. Granulocyte-colony stimulating factor following peripheral-blood progenitor transplant in non-Hodgkin's lymphoma. _J Clin Oncol_

1995; 13: 935–941. Article  CAS  PubMed  Google Scholar  * Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, Macdonald JS . Granulocyte-colony stimulating factors accelerates neutrophil

engraftment following peripheral- blood stem cell transplantation:a prospective randomized trial. _J Clin Oncol_ 1995; 13: 1323–1327. Article  CAS  PubMed  Google Scholar  * Ozer H, Armitage

JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA _et al_. American Society of Clinical Oncology: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors:

evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. _J Clin Oncol_ 2000; 18: 3558–3585. Article  CAS  PubMed  Google Scholar  *

Colby C, McAfee SL, Finkelstein DM, Spitzer TR . Early vs delayed administration of G-CSF following autologous peripheral blood stem cell transplantation. _Bone Marrow Transplant_ 1998; 21:

1005–1010. Article  CAS  PubMed  Google Scholar  * Taylor KM, Jagannath S, Spitzer G, Spinolo JA, Tucker SL, Fogel B _et al_. Recombinant human granulocyte colony-stimulating factor hastens

granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. _J Clin Oncol_ 1989; 7: 1791–1799. Erratum in: _J Clin Oncol_ 1990; 8:

567. Article  CAS  PubMed  Google Scholar  * Madero L, Muonz A, Diaz de Heredia A, Martinez A, Badell I, Esquembre C _et al_. G-CSF after autologous bone marrow transplantation for

malignant diseases in children. Spanish Working Party for Bone Marrow Transplantation in Children. _Bone Marrow Transplant_ 1995; 15: 349–351. CAS  PubMed  Google Scholar  * Souetre E, Qing

W, Penelaud PF . Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantation. _Eur J Cancer_ 1996; 32A: 1162–1165.

Article  CAS  PubMed  Google Scholar  * Schmitz N, Ljungman P, Cordonnier C, Kempf C, Linkesch W, Alegre A _et al_. Lenograstim after autologous peripheral blood progenitor cell

transplantation: results of a double-blind, randomized trial. _Bone Marrow Transplant_ 2004; 34: 955–962. Article  CAS  PubMed  Google Scholar  * Piccirillo N, Sica S, Laurenti L, Chiusolo

P, La Barbera EO, Sorà F _et al_. Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation. _Bone Marrow Transplant_ 1999; 23:

1245–1250. Article  CAS  PubMed  Google Scholar  * Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P _et al_. A new form of Filgrastim with sustained duration _in vivo_ and

enhanced ability to mobilize PBPC in both mice and humans. _Exp Hematol_ 1999; 27: 1724–1734. Article  CAS  PubMed  Google Scholar  * Layton JE, Hockman H, Sheridan WP, Morstyn G . Evidence

for a novel _in vivo_ control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. _Blood_ 1989; 74: 1303–1307. CAS  PubMed  Google Scholar  * Van Der

Auwera P, Platzer E, Xu ZX, Schulz R, Feugeas O, Capdeville R _et al_. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25–8315) in

healthy volunteers: comparison with single and multiple daily doses of filgrastim. _Am J Hematol_ 2001; 66: 245–251. Article  CAS  PubMed  Google Scholar  * Centers for Disease Control and

Prevention (CDC). Centers for Disease Control and Prevention guidelines for the prevention of intravascular catheter-related infections. _MMWR Morb Mortal Wkly Rep_ 2002; 51: 27–28. Google

Scholar  * McQuaker IG, Haynes AP, Anderson S, Stainer C, Owen RG, Morgan GJ _et al_. Engraftment and molecular monitoring of CD34+ peripheral-blood stem-cell transplants for follicular

lymphoma: a pilot study. _J Clin Oncol_ 1997; 15: 2288–2295. Article  CAS  PubMed  Google Scholar  * Valteau-Couanet D, Faucher C, Auperin A, Michon J, Milpied N, Boiron JM _et al_. Cost

effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial. _Bone Marrow Transplant_ 2005; 36: 547–552. Article  CAS  PubMed

  Google Scholar  * George S, Yunus F, Case D, Yang BB, Hackett J, Shogan JE _et al_. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's

lymphoma. _Leuk Lymphoma_ 2003; 44: 1691–1696. Article  CAS  PubMed  Google Scholar  * Holmes FA, Jones SE, O’Shaughnessy J, Vukelja S, George T, Savin M _et al_. Comparable efficacy and

safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. _Ann Oncol_

2002; 13: 903–909. Article  CAS  PubMed  Google Scholar  * Holmes FA, O’Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M _et al_. Blinded, randomized, multicenter study to evaluate

single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. _J Clin Oncol_

2002; 20: 727–731. Article  CAS  PubMed  Google Scholar  * Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L _et al_. Randomized, dose-escalation study of SD/01 compared

with daily filgrastim in patients receiving chemotherapy. _J Clin Oncol_ 2000; 18: 2522–2528. Article  CAS  PubMed  Google Scholar  * Green MD, Koelbl H, Baselga J, Galid A, Guillem V,

Gascon P _et al_. International Pegfilgrastim 749 Study Group: a randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim

in patients receiving myelosuppressive chemotherapy. _Ann Oncol_ 2003; 14: 29–35. Article  CAS  PubMed  Google Scholar  * Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J

_et al_. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. _J Clin Oncol_ 2003; 21: 514–519. Article  CAS  PubMed 

Google Scholar  * Jagasia MH, Greer JP, Morgan DS, Mineishi S, Kassim AA, Ruffner KL _et al_. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant:

phase II study. _Bone Marrow Transplant_ 2005; 35: 1165–1169. Article  CAS  PubMed  Google Scholar  * Laurenti L, Piccioni P, Piccirillo N, Sora F, Chiusolo P, Garzia M _et al_. Immune

recovery of lymphocyte subsets 6 years after autologous peripheral blood stem cell transplantation (PBSCT) for lymphoproliferative diseases. A comparison between NHL, HD and MM in group of

149 patients. _Leuk Lymphoma_ 2004; 45: 2063–2070. Article  PubMed  Google Scholar  * Albo C, de la Fuente J, Ares C, Alonso C, Feteira E . Kinetics and immunophenotypic characterization of

circulating hematopoietic progenitor cells after peripheral blood stem cell transplantation. _Haematologica_ 2004; 89: 845–851. PubMed  Google Scholar  Download references ACKNOWLEDGEMENTS

This work was supported in part by Associazione Italiana per la Ricerca contro il Cancro (AIRC) Milan, Italy. We are grateful to the nursing staff of the Divisione Ematologia, Policlinico A

Gemelli. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Haematology Institute, A Gemelli Hospital, Catholic University, Rome, Italy N Piccirillo, S De Matteis, S De Vita, L Laurenti, P

Chiusolo, F Sorà, G Reddiconto, G d'Onofrio, G Leone & S Sica Authors * N Piccirillo View author publications You can also search for this author inPubMed Google Scholar * S De

Matteis View author publications You can also search for this author inPubMed Google Scholar * S De Vita View author publications You can also search for this author inPubMed Google Scholar

* L Laurenti View author publications You can also search for this author inPubMed Google Scholar * P Chiusolo View author publications You can also search for this author inPubMed Google

Scholar * F Sorà View author publications You can also search for this author inPubMed Google Scholar * G Reddiconto View author publications You can also search for this author inPubMed 

Google Scholar * G d'Onofrio View author publications You can also search for this author inPubMed Google Scholar * G Leone View author publications You can also search for this author

inPubMed Google Scholar * S Sica View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to N Piccirillo. RIGHTS AND

PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Piccirillo, N., De Matteis, S., De Vita, S. _et al._ Kinetics of peg-filgrastim after high-dose chemotherapy and

autologous peripheral blood stem cell transplantation. _Bone Marrow Transplant_ 40, 579–583 (2007). https://doi.org/10.1038/sj.bmt.1705772 Download citation * Received: 30 November 2006 *

Revised: 03 May 2007 * Accepted: 03 May 2007 * Published: 16 July 2007 * Issue Date: September 2007 * DOI: https://doi.org/10.1038/sj.bmt.1705772 SHARE THIS ARTICLE Anyone you share the

following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer

Nature SharedIt content-sharing initiative KEYWORDS * febrile neutropenia * G-CSF * peg-filgrastim * autologous peripheral blood stem cell transplantation